Compass Therapeutics Inc.
NASDAQ:CMPX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
S
|
Sekisui Jushi Corp
TSE:4212
|
JP |
|
Airtac International Group
TWSE:1590
|
CN |
|
Parshva Enterprises Ltd
BSE:542694
|
IN |
EV/EBITDA
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBITDA returns to its Industry Average (13.3), the stock would be worth $-6.58 (207% downside from current price).
| Scenario | EV/EBITDA Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -12.4 | $6.14 |
0%
|
| Industry Average | 13.3 | $-6.58 |
-207%
|
| Country Average | 14.4 | $-7.1 |
-216%
|
Forward EV/EBITDA
Today’s price vs future ebitda
Peer Comparison
| Market Cap | EV/EBITDA | P/E | ||||
|---|---|---|---|---|---|---|
| US |
C
|
Compass Therapeutics Inc.
NASDAQ:CMPX
|
1.2B USD | -12.4 | -16.5 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | -194 446.1 | -160 127.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
369.5B USD | 14.7 | 88.3 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
188.3B USD | 14.4 | 24.8 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
171.9B USD | 12.6 | 20.1 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | -581 | -533.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
110.7B USD | 21.3 | 28.3 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
78.9B USD | 13 | 17.6 | |
| NL |
|
argenx SE
XBRU:ARGX
|
44.4B EUR | 43.6 | 40.2 | |
| AU |
|
CSL Ltd
ASX:CSL
|
66.3B AUD | 10.9 | 32.4 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | -66.6 | -61.8 |
Market Distribution
| Min | 0 |
| 30th Percentile | 10 |
| Median | 14.4 |
| 70th Percentile | 21.5 |
| Max | 1 767 274.1 |
Other Multiples
Compass Therapeutics Inc.
Glance View
Compass Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of proprietary antibody therapeutics. The company is headquartered in Boston, Massachusetts and currently employs 24 full-time employees. The company went IPO on 2020-11-13. Its pipeline of product candidates includes both angiogenesis-targeted agents and immune-oncology focused agents. These product candidates are designed for anti-tumor response to cancer. Its lead product candidate, CTX-471, is a monoclonal antibody agonist of CD137, a co-stimulatory receptor on immune cells. Its second product candidate, CTX-8371, is a bispecific antibody that simultaneously targets both PD-1 and PD-L1, the targets of checkpoint inhibitor antibodies. In addition to CTX-471 and CTX-8371, It is also developing a portfolio of bispecific and monoclonal antibody product candidates, which are in preclinical development. Its product candidate, CTX-009, is an anti-DLL4 x VEGF-A bispecific antibody, which has added to its pipeline through Trigr Therapeutics, Inc. (TRIGR).
